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ill-planned surgical procedure had been previously attempted.
They did not explain how they made their decision.
In the last century, surgeons treated the congenital vascular
malformation (CVM) solely through a surgical approach. This
“cavalier approach,” with limited knowledge of the natural history
of these lesions, often resulted in extremely poor outcomes with
high morbidity and high rates of recurrence. Dismal outcomes
were due to the natural biologic behavior of the CVM lesion.
Surgeons later learned that the embryological characteristics of the
CVMs play a critical role in its behavior.
All CVM lesions derived from an “earlier” stage of embryo-
genesis maintain their mesenchymal cell characteristics, such that
they proliferate when stimulated by incomplete excision or simple
ligation of a feeding artery. These embryonic tissue remnants,
classified as “extratruncular” lesions, are often surgically inaccessi-
ble and difficult to remove completely. Therefore, only a carefully
planned multidisciplinary approach, combining both endovascular
therapy and open surgical treatment, is able to deliver a successful
outcome, as the authors demonstrated beautifully.
Second, the authors have made a critical decision to limit the
extent of the coil embolization therapy and stent grafting, and
utilized the endovascular therapy as a means to reduce the risk of
massive bleeding during the subsequent surgery. They did not rely
solely on an endovascular approach as an independent and perma-
nent treatment. Again, they did not explain their rational of this
approach.
Up until a few decades ago, simple ligation/ablation of a
feeding artery of an AVM lesion was often performed without
knowledge of the characteristics of extratruncular AVM lesions.
This maneuver deprives the AVM lesion of its arterial supply only
temporarily, which then ultimately stimulates this embryonic tissue
remnant with mesenchymal cell characteristics. The nidus of the
lesion will soon proliferate and develop new arterial collaterals via
“neovascular recruitment,” making the condition worse. There-
fore, ligation/ablation of the feeding artery as a sole, permanent
treatment should no longer be practiced as the authors wisely
demonstrated.
Third, the authors made another critical decision to perform
ethanol sclerotherapy3 prior to surgical excision. This was a wise
decision. As before, they did not explain clearly their rationale and
why they took this approach.
The only way to achieve a curative resection of an extratruncular
AVM lesion is to completely destroy the endothelial cells of the nidus
in order to prevent its recurrence. Ethanol is the only sclerotherapy
agent that has been shown to deliver permanent destruction of the
lesion nidus (with mesenchymal cell characteristics). Because this
extratruncular lesion is not a well localized one, but rather a diffusely
infiltrating lesion, preoperative embolization therapy with N-butyl
cyanoacrylate would not have been as good a choice as ethanol
sclerotherapy to deliver effective local control. Ethanol sclerotherapy
provided extra reassurance of permanent destruction of any potential
residual cells present following excision.
The authors have successfully utilized a multidisciplinary ap-
proach to the treatment of a high risk AVM lesion,4 combining
both endovascular therapies with open surgical resection, resulting
in an excellent outcome. We continue to support and promote this
multidisciplinary approach to the AVM.
Byung-Boong Lee, MD, PhD
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Reply
I appreciate your comments about my article1 entitled “Mul-
tidisciplinary approach in the management of a giant arteriovenous
malformation.”
The only reason I did not explain in detail why I chose the
multidisciplinary approach to treat this AVM (endovascular thera-
pies plus open surgical resection) was that I had to write the case
using only 350 words (as a Vascular Image). I agree with all your
comments, and I also think that the multidisciplinary approach is
the best strategy to treat these lesions.
Célio Teixeira Mendonça, MD, PhD
Positivo University
Curitiba, Brazil
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Regarding “Pharmacologic risk factor management in
peripheral arterial disease: A vade mecum for vascular
surgeons”
The excellent article by Rehring et al1 suggests specific recom-
mendations for tobacco cessation, blood pressure control, lipid-
lowering agents, and antiplatelet therapy in patients with periph-
eral arterial disease (PAD). A risk factor that perhaps deserves more
extensive discussion is the presence of diabetes mellitus (DM) in
these patients.
The authors mention that, “there are little data to support that
aggressive control of blood glucose levels improves risk of MI,
stroke, vascular death, or amputation.”1 The results of an earlier
study comparing the severity and outcome of PAD inDM (n 58)
and non-DM (n  68) patients may be of interest.2 This study
showed that during a follow-up period of 4.47  1.25 years for
DM vs 4.52  1.23 years for non-DM patients (P  .85), DM
patients were five times more likely than non-DM patients to
undergo an amputation (41.4% vs 11.5%), with an odds ratio (OR)
of 5.4 (95% confidence interval [CI], 2.3-12.9; P  .0001) and
three times more likely to die (51.7% vs 25.6%), with an OR of 3.1
(95% CI, 1.5-6.4; P  .002).2
As reported in a Consensus Statement of the American Dia-
betes Association, “the natural history of PAD in diabetic patients
has not specifically been studied longitudinally, but it is known
from prospective clinical trials of risk interventions that the cardio-
vascular event rates in patients with PAD and diabetes are higher
than those of their nondiabetic counterparts.”3 This can also be
extrapolated from the fact that “PAD is marker of systemic vascular
disease involving coronary, cerebral and renal vessels, leading to an
elevated risk of events, such as myocardial infarction, stroke, and
death.”3
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